$HOTH
Hoth Therapeutics Inc Stock $hoth

$hoth Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025455 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$927.1K	$1.773M	$5.150M
YoY Change	-36.43%	42.46%	-11.01%
% of Gross Profit
Research & Development	$890.8K	$1.474M	$4.845M
YoY Change	-9.98%	-24.68%	-35.66%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.193M	$3.421M	$11.07M
YoY Change	-17.58%	1.21%	-21.53%
Operating Profit	-$2.193M		-$11.07M
YoY Change	-17.58%		-21.53%
Interest Expense	$9.310K	-$468.0K	-$757.5K
YoY Change	-80.4%
% of Operating Profit
Other Income/Expense, Net	$9.310K	$410.3K	-$306.4K
YoY Change	-77.67%	-510.39%	44.34%
Pretax Income	-$2.184M	-$3.479M	-$11.37M
YoY Change	-15.09%	-0.04%	-20.55%
Income Tax
% Of Pretax Income
Net Earnings	-$2.184M	-$3.479M	-$11.37M
YoY Change	-15.09%	-0.04%	-20.55%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.88		-$9.50
Diluted Earnings Per Share	-$0.88	-$2.68	-$8.79
COMMON SHARES
Basic Shares Outstanding	3.302M shares	1.300M shares	1.198M shares
Diluted Shares Outstanding	2.483M shares		1.198M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.23M	$6.638M	$6.638M
YoY Change	59.54%	-36.36%	-36.36%
Cash & Equivalents	$13.04M	$6.429M
Short-Term Investments	$190.5K	$209.3K	$209.3K
Other Short-Term Assets	$193.7K	$88.45K	$88.45K
YoY Change	2.11%	-5.87%	-5.87%
Inventory
Prepaid Expenses	$193.7K	$88.45K
Receivables
Other Receivables
Total Short-Term Assets	$13.43M	$6.726M	$6.726M
YoY Change	57.33%	-36.39%	-36.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$33.00K	$33.00K	$33.00K
YoY Change	-91.95%	-91.95%	-91.95%
Other Assets
YoY Change
Total Long-Term Assets	$33.00K	$33.00K	$33.00K
YoY Change	-91.95%	-91.95%	-91.95%
TOTAL ASSETS
Total Short-Term Assets	$13.43M	$6.726M	$6.726M
Total Long-Term Assets	$33.00K	$33.00K	$33.00K
Total Assets	$13.46M	$6.759M	$6.759M
YoY Change	50.49%	-38.47%	-38.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$782.8K	$695.0K	$695.0K
YoY Change	11.86%	92.54%	92.54%
Accrued Expenses	$530.1K	$667.7K	$692.7K
YoY Change	320.88%	56.44%	36.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.346M	$1.388M	$1.388M
YoY Change	63.01%	59.92%	59.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$250.0K	$250.0K	$250.0K
YoY Change	6.38%	6.38%	6.38%
Total Long-Term Liabilities	$250.0K	$250.0K	$250.0K
YoY Change	6.38%	6.38%	6.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.346M	$1.388M	$1.388M
Total Long-Term Liabilities	$250.0K	$250.0K	$250.0K
Total Liabilities	$1.596M	$1.638M	$1.638M
YoY Change	50.46%	48.51%	48.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.28M	-$45.10M
YoY Change		33.72%
Common Stock	$330.00	$130.00
YoY Change		-94.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.87M	$5.122M	$5.122M
YoY Change
Total Liabilities & Shareholders Equity	$13.46M	$6.759M	$6.759M
YoY Change	50.49%	-38.47%	-38.47%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.184M	-$3.479M	-$11.37M
YoY Change	-15.09%	-0.04%	-20.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.289M	-$2.550M	-$9.298M
YoY Change	7.16%	-34.65%	-23.1%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$7.500K	$74.00K
YoY Change	-100.0%	-142.93%	-163.26%
Acquisitions
YoY Change
Other Investing Activities		$10.00	$1.236M
YoY Change		-200.0%	-2653.63%
Cash From Investing Activities		-$7.490K	$1.162M
YoY Change		-57.15%	-802.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.911M	50.99K	$6.036M
YoY Change			-66.82%
NET CHANGE
Cash From Operating Activities	-$2.289M	-2.550M	-$9.298M
Cash From Investing Activities		-7.490K	$1.162M
Cash From Financing Activities	$8.911M	50.99K	$6.036M
Net Change In Cash	$6.622M	-2.507M	-$2.100M
YoY Change		-36.05%	-135.36%
FREE CASH FLOW
Cash From Operating Activities	-$2.289M	-$2.550M	-$9.298M
Capital Expenditures	$0.00	$7.500K	$74.00K
Free Cash Flow	-$2.289M	-$2.558M	-$9.372M
YoY Change	8.43%	-34.16%	-21.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38803
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1553794
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Rockefeller Plaza
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1039
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10020
CY2022	dei	Local Phone Number LocalPhoneNumber	756-2997
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	HOTH
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	13100000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3302113	shares
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	New York
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6428611	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8538270	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1892837	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88450	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93972	usd
CY2021Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	50000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6726381	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10575079	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	410000	usd
CY2022Q4	us-gaap	Assets Assets	6759381	usd
CY2021Q4	us-gaap	Assets Assets	10985079	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	694989	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360964	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	667742	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426823	usd
CY2022Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	25000	usd
CY2021Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	80000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1387731	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	867787	usd
CY2022Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	250000	usd
CY2021Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	235000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1637731	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1102787	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1302113	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1302113	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	959009	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	959009	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	130	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50198630	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43591773	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45099116	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33727163	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22006	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17586	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6759381	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10985079	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4844578	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7354708	usd
CY2022	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	86586	usd
CY2021	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	174782	usd
CY2022	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	2588595	usd
CY2021	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	3036034	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	2494132	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	2703837	usd
CY2022	hoth	Rent Expenses RentExpenses	66834	usd
CY2021	hoth	Rent Expenses RentExpenses	46871	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	984829	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	785208	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11065554	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	14101440	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11065554	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14101440	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-386909	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-152682	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-377000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	6370	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	451140	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59583	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-306399	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-212265	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11371953	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14313705	usd
CY2022	hoth	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	4420	usd
CY2021	hoth	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	32937	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11367533	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14280768	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-990	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11370963	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14280768	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.5
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-16.02
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1197521	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	893226	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4645593	usd
CY2021	hoth	Net Of Offering Costs NetOfOfferingCosts	1591600	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13407632	usd
CY2021	hoth	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	572500	usd
CY2021	hoth	Issuance Of Common Stock And Warrantnet Of Offering Costs IssuanceOfCommonStockAndWarrantnetOfOfferingCosts	4427501	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	359513	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1322821	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	32937	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14313705	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	620798	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1014896	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5985103	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-10	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4420	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11371953	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11371953	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14313705	usd
CY2022	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	34000	usd
CY2021	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	92470	usd
CY2022	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures	377000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	620798	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1322821	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-567692	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-41808	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	119870	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-176974	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-59583	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3847	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5420	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	590632	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	535340	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9297854	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12090129	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	74000	usd
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	116970	usd
CY2021	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-2556135	usd
CY2022	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	1235695	usd
CY2021	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	2507750	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1161695	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165355	usd
CY2021	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO	13407632	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4427501	usd
CY2022	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost	5985103	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1000	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	-10	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	359513	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	50000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6036093	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18194646	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9593	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-30562	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2100066	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5939162	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2629670	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6428611	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	140000	shares
CY2022Q4	hoth	Common Stock Shares Purchase CommonStockSharesPurchase	1860000	shares
CY2022Q4	hoth	Warrants Purchase To Shares WarrantsPurchaseToShares	2500000	shares
CY2022Q4	hoth	Common Stock At Purchase Price CommonStockAtPurchasePrice	5
CY2022	hoth	Aggregate Gross Proceeds AggregateGrossProceeds	10000000	usd
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5
CY2022	hoth	Warrant Exercisable Term Description WarrantExercisableTermDescription	The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	455791	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	510875	shares
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of credit risk and off-balance sheet risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	250000	usd
CY2022	hoth	Vesting Period Description VestingPeriodDescription	These options generally vest over a one to five year period
CY2022	hoth	Schedule Of Research And Development Expenses For Licenses Acquired ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">66,586</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">99,782</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Chelexa Biosciences, Inc. and the University of Cincinnati</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">86,586</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">174,782</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 156.75pt"> </p>
CY2022	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	86586	usd
CY2021	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	174782	usd
CY2022	hoth	License Maintenance Fee LicenseMaintenanceFee	14000	usd
CY2021	hoth	Related With Warrants Granted RelatedWithWarrantsGranted	100000	usd
CY2022Q4	us-gaap-sup	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0	pure
CY2021Q4	us-gaap-sup	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	150	pure
CY2022	us-gaap	Insurance Commissions And Fees InsuranceCommissionsAndFees	28000	usd
CY2022	hoth	Annual Minimum Payment AnnualMinimumPayment	150000	usd
CY2022	hoth	Annual Minimum Payments Term AnnualMinimumPaymentsTerm	P5Y
CY2022	hoth	Annual Maintenance Fees AnnualMaintenanceFees	125000	usd
CY2021	hoth	Annual Minimum Payment AnnualMinimumPayment	285000	usd
CY2021	hoth	Annual Minimum Payments Term AnnualMinimumPaymentsTerm	P5Y
CY2021	hoth	Annual Maintenance Fees AnnualMaintenanceFees	30000	usd
CY2022	hoth	Annual License Maintenance Fee AnnualLicenseMaintenanceFee	2500	usd
CY2022	hoth	Yearly Minimum Annual Royalty Fee YearlyMinimumAnnualRoyaltyFee	5000	usd
CY2022	hoth	Note Receivable NoteReceivable	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4-Note Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the sublicense agreement dated July 30, 2020 by and between the Company and Isoprene Pharmaceuticals, Inc. (“Isoprene”), the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note was due to mature on September 10, 2022 and accrued interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note could not be prepaid without the prior written consent of the Company; provided, however, that if the Isoprene Note had not been converted in connection with a Qualified Financing (as defined herein) or a Change of Control (as defined in the Isoprene Note) by the two year anniversary of the date of the issuance of the Isoprene Note, Isoprene could elect, in its sole discretion, to repay the Isoprene Note and any accrued interest thereon. In the event a Qualified Financing occurred before the Isoprene Note was repaid in full on the maturity date or the conversion of such note pursuant to a Change of Control, the Isoprene Note could be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price. “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurred before the Isoprene Note was repaid in full on the maturity date or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note could be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control. As of the maturity date of the Isoprene Note, neither a Qualified Financing nor a Change of Control had occurred, and the Isoprene Note of $50,000 and accrued interest of approximately $6,000 was paid off on October 21, 2022.</p>
CY2022	us-gaap	Financing Receivable Purchased With Credit Deterioration Amount At Purchase Price FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice	15000000	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	50000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	119870	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-176974	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-567692	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-41808	usd
CY2022	us-gaap	Dividend Income Operating DividendIncomeOperating	60913	usd
CY2021	us-gaap	Dividend Income Operating DividendIncomeOperating	66100	usd
CY2022	hoth	Other Income Nets OtherIncomeNets	-386909	usd
CY2021	hoth	Other Income Nets OtherIncomeNets	-152682	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1892837	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	410000	usd
CY2021Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	50000	usd
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-377000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2020Q1	hoth	Purchased Percentage PurchasedPercentage	5	usd
CY2020Q1	hoth	Outstanding Membership Interests OutstandingMembershipInterests	250000	usd
CY2020Q1	hoth	Membership Interests MembershipInterests	0.25	pure
CY2020Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3000000	usd
CY2020Q1	us-gaap	Purchase Options Land PurchaseOptionsLand	250000	usd
CY2020Q1	hoth	Interest Purchase Agreement InterestPurchaseAgreement	0.01	pure
CY2022	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	100000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	400000	usd
CY2021Q4	us-gaap	Other Investments OtherInvestments	0	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	350000	usd
	us-gaap	Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1 ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1	27000	usd
CY2022Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	33000	usd
CY2021Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	60000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	99010	shares
CY2021Q1	hoth	Warrants To Purchase Of Common Stock Shares WarrantsToPurchaseOfCommonStockShares	49505	shares
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4600000	usd
CY2021Q1	hoth	Issuance Term IssuanceTerm	P5Y
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	56.25
CY2021Q1	hoth	Closing Term ClosingTerm	P5Y
CY2021Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	13500000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	49.375	usd
CY2021Q1	hoth	Closing Term ClosingTerm	P3Y
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	46.5
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	140000	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2500000	shares
CY2022Q4	hoth	Purchase Price Per Share PurchasePricePerShare	5
CY2022Q4	hoth	Accompanying Warrant Per Share AccompanyingWarrantPerShare	0.001
CY2022Q4	hoth	Gross Proceeds GrossProceeds	10000000	usd
CY2022Q4	hoth	Common Stock Warrant Term Description CommonStockWarrantTermDescription	Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2022Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	66878	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	385	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	46.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	31
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4285	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	30.89
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	100	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5075	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.16
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1791	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	7.17
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3384	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.16
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y5M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	14.75
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.961	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27571	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	112.94
CY2021	hoth	Rfl Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 rfl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	25280	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	52.75
CY2021	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued	P9Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	52851	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	84.15
CY2021	hoth	Weighted Average Remaining Contractual Lifein Years Outstanding Ending Balance WeightedAverageRemainingContractualLifeinYearsOutstandingEndingBalance	P8Y7M6D
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	51800	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.75
CY2022	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued	P9Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
CY2022	hoth	Weighted Average Remaining Contractual Lifein Years Outstanding Ending Balance WeightedAverageRemainingContractualLifeinYearsOutstandingEndingBalance	P8Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	104651	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	49.8
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	0	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	620798	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1322821	usd
CY2022	hoth	Schedule Of Warrant Activity ScheduleOfWarrantActivity	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">49,417</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">696,334</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.4</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,643</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44.92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,151</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,069</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49.83</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49.83</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">401,312</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.5</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p>
CY2022	hoth	Leases Office Spaces LeasesOfficeSpaces	4500	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	67000	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	47000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10378471	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6752718	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	444866	usd
CY2022Q4	hoth	Capitalized Research Costs CapitalizedResearchCosts	1211477	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	670035	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	590050	usd
CY2022Q4	hoth	Licenses Acquired LicensesAcquired	338239	usd
CY2021Q4	hoth	Licenses Acquired LicensesAcquired	341171	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	72	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	215152	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	155816	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12813374	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8284693	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12813374	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8284693	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.095	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.082	pure
CY2022	hoth	Impact Of Non Us Earnings ImpactOfNonUSEarnings	0	pure
CY2021	hoth	Impact Of Non Us Earnings ImpactOfNonUSEarnings	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.009	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.018	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.067	pure
CY2022	hoth	Equity Compensationin Dollars EquityCompensationinDollars	0.001	pure
CY2021	hoth	Equity Compensationin Dollars EquityCompensationinDollars	0.024	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.024	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0	pure
CY2022	hoth	Rtp And Other RTPAndOther	0.10	pure
CY2021	hoth	Rtp And Other RTPAndOther	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.396	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.30	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.038	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	32900000	usd
CY2022	us-gaap	Interest Income Securities Taxable InterestIncomeSecuritiesTaxable	65800000	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	1500000	usd
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	31400000	usd
CY2017Q4	hoth	Taxable Income TaxableIncome	0.80	pure
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1200000	usd
CY2022	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	In general, an ownership change, as defined by Section 382 and 383 of the Code, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period.
CY2022Q4	us-gaap	Subsequent Event Description SubsequentEventDescription	the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which it agreed to sell an aggregate of (i) 140,000 shares of common stock, (ii) December Pre-Funded Warrants to purchase up to 1,860,000 shares of common stock and (iii) December Common Stock Warrants to purchase up to 2,500,000 shares of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each December Pre-Funded Warrant and accompanying warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses.
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Entity Registrant Name EntityRegistrantName	Hoth Therapeutics, Inc.
CY2022	dei	City Area Code CityAreaCode	(646)
CY2022Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	hoth	Preferred Stock Value1 PreferredStockValue1		usd
CY2021Q4	hoth	Preferred Stock Value1 PreferredStockValue1		usd
CY2022Q4	hoth	Preferred Stock Value2 PreferredStockValue2		usd
CY2021Q4	hoth	Preferred Stock Value2 PreferredStockValue2		usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
CY2021	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2022	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities		usd
CY2022	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost		usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure		usd
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2021	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	hoth	Deferred Income Tax Assets Depreciation Fixed Assets Gross DeferredIncomeTaxAssetsDepreciationFixedAssetsGross		usd
CY2021Q4	hoth	Deferred Income Tax Assets Depreciation Fixed Assets Gross DeferredIncomeTaxAssetsDepreciationFixedAssetsGross		usd
CY2022Q4	hoth	Accruals And Other Temporary Differences Gross AccrualsAndOtherTemporaryDifferencesGross		usd
CY2021Q4	hoth	Accruals And Other Temporary Differences Gross AccrualsAndOtherTemporaryDifferencesGross		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001711786

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-025455-index-headers.html	Edgar Link	pending
0001213900-23-025455-index.html	Edgar Link	pending
0001213900-23-025455.txt	Edgar Link	pending
0001213900-23-025455-xbrl.zip	Edgar Link	pending
ex10-5_001.jpg	Edgar Link	pending
f10k2022ex10-36_hoththera.htm	Edgar Link	pending
f10k2022ex10-5_hoththera.htm	Edgar Link	pending
f10k2022ex21-1_hoththera.htm	Edgar Link	pending
f10k2022ex23-1_hoththera.htm	Edgar Link	pending
f10k2022ex31-1_hoththera.htm	Edgar Link	pending
f10k2022ex31-2_hoththera.htm	Edgar Link	pending
f10k2022ex32-1_hoththera.htm	Edgar Link	pending
f10k2022ex4-5_hoththera.htm	Edgar Link	pending
f10k2022_hoththera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hoth-20221231.xsd	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
hoth-20221231_cal.xml	Edgar Link	unprocessable
hoth-20221231_def.xml	Edgar Link	unprocessable
hoth-20221231_lab.xml	Edgar Link	unprocessable
hoth-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_hoththera_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOTH
Hoth Therapeutics Inc Stock $hoth

2023 Q1 Form 10-K Financial Statement

#000121390023025455 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH Hoth Therapeutics Inc Stock $hoth

2023 Q1 Form 10-K Financial Statement

#000121390023025455 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH
Hoth Therapeutics Inc Stock $hoth